KRICT | # Reversible BTK-non-ITK inhibitor

2017 한국화학연구원 신약R&D 산·연 기술교류회

KRICT 한국화학연구원

Target	
Mechanism of Action	• Bruton's tyrosine kinase inhibitor
Indication - Primary	• Hematological cancers (**mantle cell lymphoma, chronic lymphocytic leukemia**)
Indication - Expansion	• Rheumatoid arthritis (reversible BTK inhibitor) • Parkinson's disease (Abl inhibitor)
Route of Administration	• PO, QD
Competitive Advantage	• Reversible BTK inhibitor • Neither ITK nor EGFR inhibition → ADCC & improved adverse effect profiles • More active than ibrutinib in a murine xenograft model using TMD-8 cells
Data Files	• In vitro: enzymes (BTK, BTK C481S, Abl), cell (TMD-8, hPBMC) kinase profiling • In vivo: murine xenograft model using TMD-8 cells, CIA model • DMPK: CYP, metabolic stabiity, Patch clamp, solubility, PK, BBB
IP Status	• Patent filing underway
Collaboration Model	• License-out • Collaborative research under funding
Contact (Science)	• Pilho Kim(pkim@krict.re.kr, +82-42-860-7541)
Contact (Licensing)	• Moon Geun Jung (Technology marketing office, mgjung@krict.re.kr, +82-42-860-7746) • Choon-gil Kim (Technology marketing office, joykim@krict.re.kr, +82-42-860-7079) • Kyung Sun Choi (Technology marketing office, chanian@krict.re.kr, +82-42-860-7076)